샘플 요청 목록

 카트 문의
시장보고서
상품코드
1941483

자가면역질환 진단 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 제품별, 검사별, 최종 용도별, 지역별, 부문 예측(2026-2033년)

Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Type (Systemic Autoimmune Disease Diagnostics, Localized Autoimmune Disease Diagnostics), By Product, By Test, By End Use, By Region, And Segment Forecasts, 2026 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 129 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

자가면역질환 진단 시장 개요

세계의 자가면역질환 진단 시장 규모는 2025년 60억 7,000만 달러로 추정되며, 2033년에 95억 8,000만 달러에 이를 것으로 예측됩니다.

또한 2026-2033년 CAGR 5.84%를 나타낼 것으로 예측됩니다. 신생아에서 1형 당뇨병과 같은 자가면역질환의 유병률 증가와 신속한 진단에 대한 수요가 성장을 가속화하는 주요 요인으로 작용하고 있습니다.

또한, 자가면역질환 관련 연구에 대한 투자 및 자금지원에 대한 관심이 높아지고 있으며, 이는 시장 성장을 더욱 촉진하고 있습니다. 또한, 개발도상국은 시장 확대의 미개발 기회를 제공하고 있으며, 향후 몇 년 동안 큰 성장 잠재력을 가지고 있습니다.

기술 혁신의 확립과 실험실 자동화율의 확대가 시장 성장을 가속할 것으로 예측됩니다. 임상의는 첨단 기술을 도입하여 여러 검사를 동시에 실시하여 보다 신속하고 정확한 결과를 얻을 수 있습니다.

자가면역질환은 100가지가 넘는 만성 쇠약성 질환군으로 미국 인구의 약 3%가 앓고 있는 것으로 알려져 있습니다. 대표적인 질환으로는 비만, 심혈관 질환, 2형 당뇨병, 모든 유형의 암 등을 들 수 있습니다. 따라서 유전적 요인, 환경적 영향, 특정 호르몬, 특정 감염에 대한 감수성 등이 전 세계적으로 자가면역질환 유병률 증가의 주요 원인이 되고 있습니다. 2024년 9월 미국 보건위원회(National Health Council)가 발표한 기사에 따르면, 자가면역질환은 약 5,000만 명의 미국인에게 영향을 미치고 있으며, 그 중 80%는 여성이 차지하고 있습니다. 이러한 질환의 진단에는 본질적인 복잡성이 수반되기 때문에 이 수치는 과소평가된 수치일 가능성이 높습니다. 더욱 우려스러운 것은 자가면역질환이 전염병 규모에 가까워지고 있다는 사실이며, 여러 연구에서 연간 3%에서 12% 범위 증가율을 보이고 있습니다.

새로운 기술 혁신의 가속화와 이에 따른 검사 자동화 기술의 부상은 시장 확대에 크게 기여하고 있습니다. 이러한 추세는 임상의들의 첨단 기술 채택 확대에 힘입은 것으로, 다양한 검사를 실시하면서 보다 신속하고 정확한 결과를 얻을 수 있게 되었습니다. 예를 들어, 2025년 1월, Werfen은 Aptiva 항인지질 항체 증후군(APS) 면역글로불린 G(IgG) 및 면역글로불린 M(IgM) 시약에 대해 FDA의 승인을 획득했습니다. 이 검사는 항인지질항체증후군(APS) 진단의 정확도를 높여 자가면역질환 진단에 있어 중요한 미충족 수요를 충족시킬 수 있습니다.

또한, 각국 정부의 이니셔티브도 시장 발전을 뒷받침하고 있습니다. 자가면역질환센터(ACE), 자가면역질환 예방 공동연구그룹(CSGADP), 북미 류마티스 관절염 컨소시엄(NARAC)과 같은 단체의 활동은 환자와 의료진에게 적절한 진단 및 치료 프로토콜에 대한 인식을 확산시킴으로써 시장 성장에 기여하고 있습니다.

자가면역질환 센터(ACE), 자가면역질환 예방 공동연구그룹(CSGADP), 북미 류마티스 관절염 컨소시엄(NARAC) 등 자가면역질환의 적절한 진단과 치료에 대한 환자 및 의료진 교육, 자가면역질환에 대한 인식과 조기 개입을 촉진하는 단체의 참여는 자가면역질환 시장 역학에 긍정적인 영향을 미칠 것으로 예측됩니다. 시장 역학에 긍정적인 영향을 미칠 것으로 예측됩니다. 이는 자가면역질환 진단 시장의 성장을 가속할 것으로 예측됩니다. 또한, 진단 검사에 대한 접근성 향상, 질병 관리 개선, 의료 비용 절감 등을 위한 정부의 적극적인 노력도 예측 기간 동안 시장 성장을 가속할 것으로 예측됩니다.

자주 묻는 질문

  • 자가면역질환 진단 시장 규모는 어떻게 예측되나요?
  • 자가면역질환의 유병률 증가 원인은 무엇인가요?
  • 자가면역질환 진단 시장의 성장에 기여하는 요인은 무엇인가요?
  • 자가면역질환의 대표적인 질환은 무엇인가요?
  • 자가면역질환 진단 시장의 정부 지원은 어떤 형태로 이루어지고 있나요?
  • 자가면역질환 진단에 대한 새로운 기술 혁신의 예시는 무엇인가요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

제4장 유형별 비즈니스 분석

제5장 제품별 비즈니스 분석

제6장 검사별 비즈니스 분석

제7장 최종 용도별 비즈니스 분석

제8장 지역별 비즈니스 분석

제9장 경쟁 구도

LSH 26.03.11

Autoimmune Disease Diagnostics Market Summary

The global autoimmune disease diagnostics market size was estimated at USD 6.07 billion in 2025 and is projected to reach USD 9.58 billion by 2033, growing at a CAGR of 5.84% from 2026 to 2033. The increasing prevalence of autoimmune disorders such as type 1 diabetes in newborn babies, coupled with the demand for rapid diagnostics, is the key driver accentuating growth.

In addition, there is an increasing focus on investments and funding for research related to autoimmune diseases, which further propels market growth. Furthermore, developing countries offer untapped opportunities for market expansion, presenting significant growth prospects in the years to come.

The establishment of technological advancements and the expansion of lab automation rates are anticipated to boost market growth. Clinicians are implementing advanced technology to conduct several tests at the same time with faster and more precise results.

Autoimmune diseases are a group of more than 100 chronic, debilitating conditions that affect approximately 3% of the US population. Some of the most common autoimmune diseases include obesity, cardiovascular diseases, type 2 diabetes mellitus, and all cancers. Thus, genetic factors, environmental influences, specific hormones, and susceptibility to certain infections are key contributors to the rising prevalence of autoimmune diseases globally. According to an article published by the National Health Council in September 2024, autoimmune diseases affect approximately 50 million Americans, and women account for 80% of this number. Given the inherent complexity involved in diagnosing these conditions, this figure is likely understated. More concerning is the fact that autoimmune diseases are approaching epidemic proportions, with several studies indicating annual growth rates in the range of 3%-12%.

An increasing rate of novel technological advancements and the corresponding emergence of laboratory automation technologies significantly contribute to market expansion. This trend is driven by the growing adoption of advanced technologies among clinicians, enabling them to conduct a wide range of tests while achieving faster and more accurate results. For instance, in January 2025, Werfen received FDA clearance for Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) Reagents. These assays enhance the accuracy of antiphospholipid syndrome (APS) diagnosis, addressing a significant unmet need in the diagnosis of autoimmune diseases.

In addition, the implementation of government initiatives across economies supports market developments. Work by organizations such as the Autoimmunity Centers of Excellence (ACE), the Cooperative Study Group for Autoimmune Disease Prevention (CSGADP), and the North American Rheumatoid Arthritis Consortium (NARAC) contributes to market growth by creating awareness among patients and healthcare professionals regarding proper diagnosis and treatment protocols.

The involvement of organizations such as the Autoimmunity Centers of Excellence, Cooperative Study Group for Autoimmune Disease Prevention, and North American Rheumatoid Arthritis Consortium in educating patients and healthcare professionals about proper diagnosis and treatment is anticipated to have a positive impact on market dynamics, as it promotes awareness and early intervention in autoimmune diseases. This, in turn, is expected to drive the growth of the autoimmune disease diagnostics market. Besides, favorable government initiatives aimed at increasing access to diagnostic tests, improving disease management and reducing healthcare costs, among other factors, are also expected to boost market growth during the forecast period.

Global Autoimmune Disease Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global autoimmune disease diagnostics market report based on type, product, test, end use, and region.

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Systemic autoimmune disease diagnostics
    • Rheumatoid arthritis
    • Ankylosing spondylitis
    • Systemic lupus erythematosus (SLE)
    • Others
  • Localized autoimmune disease diagnostics
    • Multiple sclerosis
    • Type 1 diabetes
    • Hashimoto's Thyroiditis
    • Idiopathic thrombocytopenic purpura
    • Others
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments
  • Consumables and Assays
  • Test Outlook (Revenue, USD Million, 2021 - 2033)
  • Antinuclear antibody tests
  • Autoantibody tests
  • C-reactive Protein (CRP)
  • Complete blood count (CBC)
  • Urinalysis
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Diagnostic centers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Norway
    • Denmark
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type segment
      • 1.1.1.2. Product segment
      • 1.1.1.3. Test segment
      • 1.1.1.4. End use segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type and Test Snapshot
  • 2.3. Product and End use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Presence of research funding programs
      • 3.2.1.2. Presence of favorable government initiatives
      • 3.2.1.3. Growing patient awareness levels
      • 3.2.1.4. Technological innovation in the form of lab automation
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Slow diagnostic result turnaround times and lack of skilled healthcare practitioner
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis

Chapter 4. Type Business Analysis

  • 4.1. Autoimmune Disease Diagnostics Market: Type Movement Analysis
  • 4.2. Systemic Autoimmune Disease Diagnostics
    • 4.2.1. Systemic Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 4.2.2. Rheumatoid Arthritis Diagnostics
      • 4.2.2.1. Rheumatoid Arthritis Diagnostics Market, 2021 - 2033 (USD Million)
    • 4.2.3. Ankylosing Spondylitis Diagnostics
      • 4.2.3.1. Ankylosing Spondylitis Diagnostics Market, 2021 - 2033 (USD Million)
    • 4.2.4. Systemic Lupus Erythematosus (SLE) Diagnostics
      • 4.2.4.1. Systemic Lupus Erythematosus (SLE) Diagnostics Market, 2021 - 2033 (USD Million)
    • 4.2.5. Other Systemic Autoimmune Disease Diagnostics
      • 4.2.5.1. Other Systemic Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 4.3. Localized Disease Diagnostics
    • 4.3.1. Localized Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 4.3.2. Multiple sclerosis diagnostics
      • 4.3.2.1. Multiple sclerosis diagnostics Market, 2021 - 2033 (USD Million)
    • 4.3.3. Type 1 Diabetes Diagnostics
      • 4.3.3.1. Type 1 Diabetes Diagnostics Market, 2021 - 2033 (USD Million)
    • 4.3.4. Hashimoto's Thyroiditis Diagnostics
      • 4.3.4.1. Hashimoto's Thyroiditis Diagnostics Market, 2021 - 2033 (USD Million)
    • 4.3.5. Idiopathic Thrombocytopenic Purpura (ITP) diagnostics
      • 4.3.5.1. Idiopathic Thrombocytopenic Purpura (ITP) diagnostics Market, 2021 - 2033 (USD Million)
    • 4.3.6. Other Localized Autoimmune Disease Diagnostics
      • 4.3.6.1. Other Localized Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)

Chapter 5. Product Business Analysis

  • 5.1. Autoimmune Disease Diagnostics Market: Product Movement Analysis
  • 5.2. Instruments
    • 5.2.1. Instruments Market, 2021 - 2033 (USD Million)
  • 5.3. Consumables and Assays
    • 5.3.1. Consumables and Assays Market, 2021 - 2033 (USD Million)

Chapter 6. Test Business Analysis

  • 6.1. Autoimmune Disease Diagnostics Market: Test Movement Analysis
  • 6.2. Antinuclear Antibody Tests
    • 6.2.1. Antinuclear Antibody Tests Market, 2021 - 2033 (USD Million)
  • 6.3. Autoantibody Tests
    • 6.3.1. Autoantibody Tests Market, 2021 - 2033 (USD Million)
  • 6.4. C-reactive Protein (CRP)
    • 6.4.1. C-Reactive Protein (CRP) Market, 2021 - 2033 (USD Million)
  • 6.5. Complete Blood Count (CBC)
    • 6.5.1. Complete Blood Count (CBC) Market, 2021 - 2033 (USD Million)
  • 6.6. Urinalysis
    • 6.6.1. Urinalysis Market, 2021 - 2033 (USD Million)
  • 6.7. Others
    • 6.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. End Use Business Analysis

  • 7.1. Autoimmune Disease Diagnostics Market: End Use Movement Analysis
  • 7.2. Hospitals
    • 7.2.1. Hospitals Market, 2021 - 2033 (USD Million)
  • 7.3. Diagnostic Centers
    • 7.3.1. Diagnostic Centers Market, 2021 - 2033 (USD Million)
  • 7.4. Others
    • 7.4.1. Others Market, 2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

  • 8.1. Autoimmune Disease Diagnostics Market Share By Region, 2024 & 2030
  • 8.2. North America
    • 8.2.1. SWOT Analysis
    • 8.2.2. North America Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.3. U.S.
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Target Disease Prevalence
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Regulatory Framework
      • 8.2.3.5. U.S. Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.4. Canada
      • 8.2.4.1. Key Country Dynamics
      • 8.2.4.2. Target Disease Prevalence
      • 8.2.4.3. Competitive Scenario
      • 8.2.4.4. Regulatory Framework
      • 8.2.4.5. Canada Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.2.5. Mexico
      • 8.2.5.1. Key Country Dynamics
      • 8.2.5.2. Target Disease Prevalence
      • 8.2.5.3. Competitive Scenario
      • 8.2.5.4. Regulatory Framework
      • 8.2.5.5. Mexico Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.3. Europe
    • 8.3.1. SWOT Analysis
    • 8.3.2. Europe Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.3. UK
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Target Disease Prevalence
      • 8.3.3.3. Competitive Scenario
      • 8.3.3.4. Regulatory Framework
      • 8.3.3.5. UK Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.4. Germany
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Target Disease Prevalence
      • 8.3.4.3. Competitive Scenario
      • 8.3.4.4. Regulatory Framework
      • 8.3.4.5. Germany Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.5. France
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Target Disease Prevalence
      • 8.3.5.3. Competitive Scenario
      • 8.3.5.4. Regulatory Framework
      • 8.3.5.5. France Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.6. Italy
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Target Disease Prevalence
      • 8.3.6.3. Competitive Scenario
      • 8.3.6.4. Regulatory Framework
      • 8.3.6.5. Italy Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.7. Spain
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Target Disease Prevalence
      • 8.3.7.3. Competitive Scenario
      • 8.3.7.4. Regulatory Framework
      • 8.3.7.5. Spain Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Target Disease Prevalence
      • 8.3.8.3. Competitive Scenario
      • 8.3.8.4. Regulatory Framework
      • 8.3.8.5. Sweden Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Target Disease Prevalence
      • 8.3.9.3. Competitive Scenario
      • 8.3.9.4. Regulatory Framework
      • 8.3.9.5. Norway Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.3.10. Denmark
      • 8.3.10.1. Key Country Dynamics
      • 8.3.10.2. Target Disease Prevalence
      • 8.3.10.3. Competitive Scenario
      • 8.3.10.4. Regulatory Framework
      • 8.3.10.5. Denmark Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. SWOT Analysis
    • 8.4.2. Asia Pacific Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.3. Japan
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Competitive Scenario
      • 8.4.3.4. Regulatory Framework
      • 8.4.3.5. Japan Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.4. China
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Competitive Scenario
      • 8.4.4.4. Regulatory Framework
      • 8.4.4.5. China Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.5. India
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Target Disease Prevalence
      • 8.4.5.3. Competitive Scenario
      • 8.4.5.4. Regulatory Framework
      • 8.4.5.5. India Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.6. Australia
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Target Disease Prevalence
      • 8.4.6.3. Competitive Scenario
      • 8.4.6.4. Regulatory Framework
      • 8.4.6.5. Australia Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Target Disease Prevalence
      • 8.4.7.3. Competitive Scenario
      • 8.4.7.4. Regulatory Framework
      • 8.4.7.5. Thailand Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.4.8. South Korea
      • 8.4.8.1. Key Country Dynamics
      • 8.4.8.2. Target Disease Prevalence
      • 8.4.8.3. Competitive Scenario
      • 8.4.8.4. Regulatory Framework
      • 8.4.8.5. South Korea Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.5. Latin America
    • 8.5.1. SWOT Analysis
    • 8.5.2. Latin America Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.3. Brazil
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Competitive Scenario
      • 8.5.3.4. Regulatory Framework
      • 8.5.3.5. Brazil Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Competitive Scenario
      • 8.5.4.4. Regulatory Framework
      • 8.5.4.5. Argentina Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
  • 8.6. Middle East and Africa
    • 8.6.1. SWOT Analysis
    • 8.6.2. Middle East and Africa Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.3. South Africa
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Competitive Scenario
      • 8.6.3.4. Regulatory Framework
      • 8.6.3.5. South Africa Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.4. Saudi Arabia
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Competitive Scenario
      • 8.6.4.4. Regulatory Framework
      • 8.6.4.5. Saudi Arabia Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.5. UAE
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Competitive Scenario
      • 8.6.5.4. Regulatory Framework
      • 8.6.5.5. UAE Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)
    • 8.6.6. Kuwait
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Competitive Scenario
      • 8.6.6.4. Regulatory Framework
      • 8.6.6.5. Kuwait Autoimmune Disease Diagnostics Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Share Analysis, 2024
  • 9.4. Company Profiles/Listing
    • 9.4.1. F. Hoffmann-La Roche Ltd
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Siemens Healthineers AG
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Abbott
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Beckman Coulter, Inc.
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. Danaher Corporation
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Quest Diagnostics
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. EUROIMMUN Medizinische Labordiagnostika AG
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. Nova Diagnostics Pte Ltd.
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. BIOMERIEUX
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. Hemagen Diagnostics, Inc.
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제